← FDA DRUG APPROVALS

FDA ANDA · ANDA078922

ZIDOVUDINE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA078922
TYPE
ANDA
ORIGINAL APPROVAL
2008-02-14
LATEST ACTION
2020-02-12
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ZIDOVUDINEDiscontinued
ZIDOVUDINE 300MG · TABLET · ORAL

Approval history

2020-02-12Labeling · Supplement 15 · standardAP
2015-06-26Labeling · Supplement 10 · standardAP
2015-06-26Labeling · Supplement 9 · standardAP
2012-03-30Labeling · Supplement 5AP
2011-03-02Labeling · Supplement 4AP
2008-02-14OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →